Cargando…
The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
BACKGROUND: Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183697/ https://www.ncbi.nlm.nih.gov/pubmed/32334639 http://dx.doi.org/10.1186/s40360-020-00408-3 |
_version_ | 1783526474182033408 |
---|---|
author | Cho, Junhyeong Na, Jeonggu Bae, Eunjin Lee, Tae Won Jang, Ha Nee Cho, Hyun Seop Chang, Se-Ho Park, Dong Jun |
author_facet | Cho, Junhyeong Na, Jeonggu Bae, Eunjin Lee, Tae Won Jang, Ha Nee Cho, Hyun Seop Chang, Se-Ho Park, Dong Jun |
author_sort | Cho, Junhyeong |
collection | PubMed |
description | BACKGROUND: Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription. METHODS: We retrospectively reviewed the medical records of 22 patients admitted with rhabdomyolysis associated with fenoverine from January 1999 to December 2014, while excluding other well-known risk factors of rhabdomyolysis. This period was subdivided into two periods, January 1999–December 2007 and January 2008–December 2014. We analyzed the clinical and laboratory characteristics, and the prognosis of fenoverine associated with rhabdomyolysis for these times. RESULTS: The incidence of rhabdomyolysis associated with fenoverine was 0.27% during the total period (22/8257), 0.34% in the first period (18/5298), and 0.14% in the second period (4/2959) (p < 0.001). Rhabdomyolysis occurred in 19 liver cirrhosis (LC) patients (2.03%), whereas only 3 cases (0.04%) occurred in non-LC patients (p < 0.001). Drug duration, total dose, muscle enzymes, and clinical characteristics were not different between the LC and non-LC groups. Acute renal failure (ARF) occurred in 5 patients in the LC group and 2 patients in the non-LC group (p = 0.227). Severity of hepatic derangement according to the Child-Pugh classification was not different between the ARF group and non-ARF group (p = 0.227). Four patients died, having complications of oliguric ARF (p = 0.005) and underlying severe LC (p = 0.017). Higher serum lactate dehydrogenase, blood urea nitrogen, creatinine, and potassium levels but lower serum sodium levels were found in the group that died (p = 0.001). CONCLUSIONS: Physicians should carefully prescribe fenoverine because it may cause rhabdomyolysis, especially in patients with LC. |
format | Online Article Text |
id | pubmed-7183697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71836972020-04-29 The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) Cho, Junhyeong Na, Jeonggu Bae, Eunjin Lee, Tae Won Jang, Ha Nee Cho, Hyun Seop Chang, Se-Ho Park, Dong Jun BMC Pharmacol Toxicol Research Article BACKGROUND: Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription. METHODS: We retrospectively reviewed the medical records of 22 patients admitted with rhabdomyolysis associated with fenoverine from January 1999 to December 2014, while excluding other well-known risk factors of rhabdomyolysis. This period was subdivided into two periods, January 1999–December 2007 and January 2008–December 2014. We analyzed the clinical and laboratory characteristics, and the prognosis of fenoverine associated with rhabdomyolysis for these times. RESULTS: The incidence of rhabdomyolysis associated with fenoverine was 0.27% during the total period (22/8257), 0.34% in the first period (18/5298), and 0.14% in the second period (4/2959) (p < 0.001). Rhabdomyolysis occurred in 19 liver cirrhosis (LC) patients (2.03%), whereas only 3 cases (0.04%) occurred in non-LC patients (p < 0.001). Drug duration, total dose, muscle enzymes, and clinical characteristics were not different between the LC and non-LC groups. Acute renal failure (ARF) occurred in 5 patients in the LC group and 2 patients in the non-LC group (p = 0.227). Severity of hepatic derangement according to the Child-Pugh classification was not different between the ARF group and non-ARF group (p = 0.227). Four patients died, having complications of oliguric ARF (p = 0.005) and underlying severe LC (p = 0.017). Higher serum lactate dehydrogenase, blood urea nitrogen, creatinine, and potassium levels but lower serum sodium levels were found in the group that died (p = 0.001). CONCLUSIONS: Physicians should carefully prescribe fenoverine because it may cause rhabdomyolysis, especially in patients with LC. BioMed Central 2020-04-25 /pmc/articles/PMC7183697/ /pubmed/32334639 http://dx.doi.org/10.1186/s40360-020-00408-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Cho, Junhyeong Na, Jeonggu Bae, Eunjin Lee, Tae Won Jang, Ha Nee Cho, Hyun Seop Chang, Se-Ho Park, Dong Jun The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) |
title | The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) |
title_full | The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) |
title_fullStr | The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) |
title_full_unstemmed | The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) |
title_short | The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) |
title_sort | incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in south korea (1999–2014) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183697/ https://www.ncbi.nlm.nih.gov/pubmed/32334639 http://dx.doi.org/10.1186/s40360-020-00408-3 |
work_keys_str_mv | AT chojunhyeong theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT najeonggu theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT baeeunjin theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT leetaewon theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT janghanee theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT chohyunseop theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT changseho theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT parkdongjun theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT chojunhyeong incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT najeonggu incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT baeeunjin incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT leetaewon incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT janghanee incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT chohyunseop incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT changseho incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 AT parkdongjun incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014 |